

2/20/06

NH561

U.S. Nuclear Regulatory Commission
Region 1
Division of Radioactive Materials Licensing
475 Allendale Road
King of Prussia, PA 19406-1415

RE: License No. 06-01060-01

030 01247

Subject: License Amendment

Dear Sir/Madam:

RECEIVED
REGION 1
2006 FEB 22 AM 10:40


Bridgeport Hospital requests the following changes in authorized users for medical use on our license:


1. Deletion of Gene Kopelson, M.D. for part 35.400
2. Addition of Steven M. Cohen, M.D. for parts 35.100; 35.200 and 35.300 including thyroid carcinoma

Enclosed is documentation of Dr. Cohen being on license 030-01265/06-06922-02 for parts 35.100 and 200 and a letter from Dr. Cohen's proctor that he had completed doing treatment for 40 patients with hyperthyroidism and 6 patients with thyroid cancer.

If there is any other material required, please contact me at (203)384-3168 or xdwish@bpthosp.org.

Sincerely,


David S. Wishko, Ph.D.
RSO


Michael Tatta
Director, Radiology Services

138466

NMCS/RGNI MATERIALS-002

267 Grant Street
P.O. Box 5000
Bridgeport, CT 06610-0120
203.384.3000



Affiliate Columbia University-College of Physicians & Surgeons
Member NewYork-Presbyterian Healthcare System
A Planetree Hospital

30 Shelburne Road
P.O. Box 9317
Stamford CT 06904-9317
203.276.1000

www.stamhealth.org

February 15, 2006

RECEIVED
REGION 1
2006 FEB 22 AM 10:40

Mr. David Wishko
Bridgeport Hospital
Radiation Medicine
267 Grant Street
Bridgeport, CT 06610

Dear Mr. Wishko:

As current Chief of Radiology and as Head of the Nuclear Medicine section of the Department of Radiology, I have supervised Steven M. Cohen, M.D. in the management and therapy of patients with Hyperthyroidism and Thyroid Cancer.

I have supervised Dr. Cohen in the work up, the decision making process including established risks and limitations, contraindications and the calculation of the proper prescribed dose for the treatment of 40 patients with Hyperthyroidism and 6 patients with Thyroid Cancer.

Dr. Cohen is trained in Diagnostic Nuclear Medicine and I believe well qualified in Therapeutic Nuclear Medicine of I131 Therapies.

Sincerely,

A handwritten signature in cursive script, reading 'Harvey L. Hecht, M.D.'.

Harvey L. Hecht, M.D.
Chief of Radiology
Head of Nuclear Medicine Section
Clinical Assistant Professor of Radiology
New York Presbyterian Hospital/Columbia Division

HLH:lrs

NRC FORM 374

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 1 OF 4 PAGES
Amendment No. 55**MATERIALS LICENSE**

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee

In accordance with the application dated
August 23, 2004,3. License number 06-06697-02 is amended in
its entirety to read as follows:1. Stamford Hospital
Department of Nuclear Medicine2. P. O. Box 9317 - Shelburne Road
Stamford, Connecticut 06904-9317

4. Expiration date September 30, 2014

5. Docket No. 030-01265/06-06922-02
Reference No.6. Byproduct, source, and/or special
nuclear materialA. Any byproduct material
permitted by 10 CFR 35.100B. Any byproduct material
permitted by 10 CFR 35.200C. Any byproduct material
permitted by 10 CFR 35.300D. Any byproduct material
permitted by 10 CFR 35.400E. Any byproduct material
permitted by 10 CFR 31.11

F. Cesium 137

Chemical and/or physical form

A. Any

B. Any

C. Any

D. Sealed Sources (3M Models
6500, 6501, 6502, and 6503;
Amersham Health Models
6711 and CDCS.T1; and
Theragenics Model 200)

E. Prepackaged Kits

F. Sealed sources (3M Models
6D6C-CA, Nos. 6500, 6501,
6502 and 6503)B. Maximum amount that licensee may
possess at any one time under this
license

A. As needed

B. As needed

C. 1000 millicuries

D. 2000 millicuries

E. 5 millicuries

F. 260 millicuries

NRC FORM 374A

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 2 of 4 PAGES

MATERIALS LICENSE SUPPLEMENTARY SHEET

License Number

06-06697-02

Docket or Reference Number

030-01265/06-06922-02

Amendment No. 55

9. Authorized use:

- A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
- B. Any imaging and localization study permitted by 10 CFR 35.200.
- C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.
- D. Any manual brachytherapy procedure permitted by 10 CFR 35.400.
- E. In vitro studies.
- F. Non-human use. For calibrations and checking of the licensee's instruments.

CONDITIONS

- 10. A. Licensed material may be used or stored only at the licensee's facilities located at Stamford Hospital, 190 West Broad Street, Stamford, Connecticut.
- B. Licensed material listed in Item 6, except Item 6.D, may also be used or stored at the Tully Health Center Building located at 32 Sawberry Hill Court, Stamford, Connecticut.
- 11. The Radiation Safety Officer for this license is Harvey L. Hecht, M.D.
- 12. Licensed material is only authorized for use by or under the supervision of:
 - A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.
 - B. The following individuals are authorized users for medical use as indicated:

Authorized Users

Material and Use

Steven M. Cohen, M.D.	35.100; 35.200; <u>In vitro</u> studies
Kristan D. Zimmermann, M.D.	35.100; 35.200; <u>In vitro</u> studies
James McSweeney, M.D.	35.100; 35.200; 35.300 except thyroid carcinoma
William Caragol, M.D.	35.100; 35.200; 35.300 except thyroid carcinoma
James Rini, M.D.	35.100; 35.200; 35.300 except thyroid carcinoma
Kelly Harkins, M.D.	35.100; 35.200
Harvey L. Hecht, M.D.	35.100; 35.200; 35.300; 35.400; <u>In vitro</u> studies Cesium 137 for instrument calibration

NRC FORM 374A

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 3 of 4 PAGES

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number

06-08697-02

Docket or Reference Number

030-01265/06-06922-02

Amendment No. 55

Authorized UsersMaterial and Use

Sean W. Dowling, M.D.

35.300; 35.400

Frank A. Masino, M.D.

35.300; 35.400

Arnold J. Schwartz, M.D.

35.300; 35.400

William Harley, M.D.

35.100; 35.200; In vitro

Thomas Di Bartholomeo, M.D.

35.100; 35.200; 35.300; In vitro studies
Cesium 137 for instrument calibration

Mark Hamet, M.D.

35.100; 35.200; 35.300

Michael King, M.D.

35.100; 35.200; 35.300


13. In addition to the possession limits in 10 CFR 30.35(d), the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.
14. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."

**MATERIALS LICENSE
 SUPPLEMENTARY SHEET**

License Number
 06-06697-02
 Docket or Reference Number
 030-01265/06-06922-02
 Amendment No. 55

15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Application dated August 23, 2004



For the U.S. Nuclear Regulatory Commission

Original signed by Michelle Beardsley

Date September 28, 2004

By

Michelle Beardsley
 Medical Branch
 Division of Nuclear Materials Safety
 Region I
 King of Prussia, Pennsylvania 19406

This is to acknowledge the receipt of your letter/application dated

2/20/2006, and to inform you that the initial processing which includes an administrative review has been performed.

☒ Amended. 06-01060-01
There were no administrative omissions. Your application was assigned to a technical reviewer. Please note that the technical review may identify additional omissions or require additional information.

☐ Please provide to this office within 30 days of your receipt of this card

A copy of your action has been forwarded to our License Fee & Accounts Receivable Branch, who will contact you separately if there is a fee issue involved.

Your action has been assigned Mail Control Number 138466.
When calling to inquire about this action, please refer to this control number.
You may call us on (610) 337-5398, or 337-5260.